n-3 Polyunsaturated Fatty Acids: Promising Nutrients for Preventing Cardiovascular Disease

Shusuke Yagi1,2,6, Daiju Fukuda1,5, Ken-ichi Aihara3, Masashi Akaike4, Michio Shimabukuro5,7 and Masataka Sata1

1 Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
2 Department of Community Medicine and Human Resource Development, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
3 Department of Community Medicine for Diabetes and Metabolic Disorders, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
4 Department of Medical Education, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
5 Department of Cardio-Diabetes Medicine, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
6 Department of Internal Medicine, Shikoku Central Hospital, Ehime, Japan
7 Department of Diabetes, Endocrinology and Metabolism, School of Medicine, Fukushima Medical University, Japan

The adoption of the Western-style diet, with decreased fish intake and lack of exercise, has increased the prevalence of cardiovascular disease (CVD) in Japan. Statin treatment has been established to reduce the risk of cardiovascular events; however, 60%–70% of these events occur despite its use. Thus, the residual risk for CVD should be identified and resolved to reduce further cardiovascular events. The serum levels of n-3 polyunsaturated fatty acids (PUFAs), including eicosapentaenoic acid and docosahexaenoic acid, are reportedly associated with an increased incidence of cardiovascular events and mortality, whereas the addition of n-3 PUFA treatment to the statin treatment decreases cardiovascular events. Similar to statins, n-3 PUFAs have pleiotropic effects in addition to lipid-modifying effects. Pre-clinical and clinical studies have shown that n-3 PUFAs prevent cardiovascular events by ameliorating endothelial function and attenuating lipid accumulation, vascular inflammation, and macrophage recruitment, thereby causing coronary plaque development and rupture. Taken together, n-3 PUFAs are comprehensively able to attenuate the atherogenic response. Therefore, n-3 PUFA intake is recommended to prevent cardiovascular events, particularly in patients with multiple cardiovascular risk factors.

Key words: Eicosapentaenoic acid, Docosahexaenoic acid, Cardiovascular disease, Residual risk

Address for correspondence: Shusuke Yagi, Department of Cardiovascular Medicine/Department of Community Medicine and Human Resource Development, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan, 3-18-15 Kuramoto-cho, Tokushima-city, Tokushima 770-8503, Japan
E-mail: syagi@tokushima-u.ac.jp
Received: July 13, 2017
Accepted for publication: July 19, 2017

Copyright©2017 Japan Atherosclerosis Society
This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.
ing one’s consumption of fish oil increases n-3 PUFA concentrations within the plasma lipids and organs.

n-3 PUFAs are derived from α-linolenic acid (ALA), whereas n-6 PUFAs are derived from linolenic acid. Both PUFAs are metabolized by desaturase and elongase (Fig. 1). Linolenic acid is metabolized to arachidonic acid (AA), which is a precursor of prostaglandins, thromboxanes, and leukotrienes. ALA is metabolized to EPA and DHA, which are precursors of prostaglandins and leukotrienes. Goyons et al. showed that nearly 7% of dietary ALA was incorporated into EPA, and only 0.013% of ALA was converted to DHA through hepatic conversion with the tracer model, which was developed based on the averaged 13C data of healthy subjects. Hussein et al. showed that 0.3% and < 0.01% of ALA is converted to EPA and DHA, respectively, in patients with hyperlipidemia. The biochemical and clinical significance of the retro conversion of DHA to EPA is unknown. Although n-3 PUFAs are essential for a healthy life, particularly for normal growth and development, only small amounts of ALA can be converted to EPA or DHA. Thus, n-3 PUFAs are called “essential fatty acids” and must be ingested as a part of the diet.

Metabolism of n-3 PUFAs

n-3 PUFAs are derived from fish and fish oil. Once consumed in the diet, n-3 PUFAs are absorbed from the gastrointestinal tract and transported to the liver as triglycerides via chylomicron particles. Upon being transported to the liver, n-3 PUFAs are used as a source of triglycerides in lipoprotein particles including low-density lipoprotein (LDL). Triglycerides mainly comprises oleic acids and saturated fatty acids, and phospholipids mainly comprises PUFAs. n-3 PUFAs are released into the blood as plasma phospholipids from the liver and incorporated into cell membrane phospholipids throughout the body; some are stored in the adipose tissue as triglycerides. Therefore, increased dietary intake of fish oil increases n-3 PUFA concentrations within the plasma lipids and organs.

n-3 PUFAs are derived from α-linolenic acid (ALA), whereas n-6 PUFAs are derived from linolenic acid. Both PUFAs are metabolized by desaturase and elongase (Fig. 1). Linolenic acid is metabolized to arachidonic acid (AA), which is a precursor of prostaglandins, thromboxanes, and leukotrienes. ALA is metabolized to EPA and DHA, which are precursors of prostaglandins and leukotrienes. Goyons et al. showed that nearly 7% of dietary ALA was incorporated into EPA, and only 0.013% of ALA was converted to DHA through hepatic conversion with the tracer model, which was developed based on the averaged 13C data of healthy subjects. Hussein et al. showed that 0.3% and < 0.01% of ALA is converted to EPA and DHA, respectively, in patients with hyperlipidemia. The biochemical and clinical significance of the retro conversion of DHA to EPA is unknown. Although n-3 PUFAs are essential for a healthy life, particularly for normal growth and development, only small amounts of ALA can be converted to EPA or DHA. Thus, n-3 PUFAs are called “essential fatty acids” and must be ingested as a part of the diet.

Metabolism of PUFAs

n-6 PUFAs are derived from fish and fish oil. Once consumed in the diet, n-6 PUFAs are absorbed from the gastrointestinal tract and transported to the liver as triglycerides via chylomicron particles. Upon being transported to the liver, n-6 PUFAs are used as a source of triglycerides in lipoprotein particles including low-density lipoprotein (LDL). Triglycerides mainly comprises oleic acids and saturated fatty acids, and phospholipids mainly comprises PUFAs. n-6 PUFAs are released into the blood as plasma phospholipids from the liver and incorporated into cell membrane phospholipids throughout the body; some are stored in the adipose tissue as triglycerides. Therefore, increased dietary intake of fish oil increases n-3 PUFA concentrations within the plasma lipids and organs.
Statins Prevent CVD by Attenuating Atherogenic Steps

The concept that atherosclerosis results from vascular inflammation is widely recognized. The accumulation of CVD risk factors provokes vascular inflammation and increases the atherosclerotic burden in the coronary and other arteries, resulting in cardiovascular events such as acute coronary syndrome (ACS). Atherosclerotic vascular inflammation comprises the following: 1) endothelial dysfunction; 2) lipid accumulation; 3) vascular inflammation and recruitment of macrophages; 4) plaque development through the proliferation and migration of smooth muscle cells (SMCs); and 5) plaque vulnerability leading to plaque rupture9).

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, called statins, inhibit the key enzyme in cholesterol biosynthesis and have been established to reduce cardiovascular events and all-cause mortality rates. Statins reduce the intracellular cholesterol synthesis and upregulate the LDL receptors in the liver, leading to reductions in the circulating levels of LDL cholesterol by 20%–60%. Furthermore, statins have both cholesterol-lowering and pleiotropic effects on the cardiovascular system, including anti-inflammatory, antioxidant, and improved nitric oxide bioavailability12-14). Statins can attenuate all the above features of atherogenesis. However, the ability of statins to reduce cardiovascular events has room for improvement, and the residual risk for CVD should be identified.

Statins Decrease n-3 PUFA Levels

Statins decrease n-3 PUFA levels. Jula et al. reported that, compared with placebo, simvastatin treatment significantly reduced DHA, but not EPA levels, in patients with hyperlipidemia15). Nozue et al. reported that pitavastatin decreased the serum DHA/AA ratio, but not the EPA/AA ratio, in patients with CVD16). Kuris et al. showed that strong statins, including atorvastatin, rosuvastatin, and pitavastatin, reduced the serum levels of EPA and DHA in proportion to decreases in LDL cholesterol in patients with CVD17). Harris et al. reported that simvastatin increased the AA/EPA and AA/DHA ratios18). Nakamura et al. reported that pravastatin and simvastatin increased serum AA levels but did not affect serum EPA levels, which resulted in a decreased EPA/AA ratio19).

The mechanisms by which statin treatment reduces EPA/AA or DHA/AA ratio or EPA and DHA levels have not been completely elucidated, but it is speculated that statin and diet therapy modulates the enzyme activity of PUFA synthesis, including desaturase and elongase (Fig. 1). Thus, patients who take statins may be recommended to take greater amounts of n-3 PUFAs to prevent cardiovascular events.

Low Serum n-3 PUFA Level is a Risk Factor for CVD

A reduced serum n-3 PUFA level is associated with an increased risk of cardiovascular events. Epidemiologic studies conducted on Greenland Inuit have shown a connection between a high seafood intake containing high n-3 PUFA levels and a low cardiovascular morbidity20). In Japan, atherosclerotic lesions, evaluated by pulse wave velocity of the aorta and intima-media thickness of the carotid artery evaluated by ultrasonography are lower in both men and women in fishing villages than in farming villages21). The Japan Public Health Center-based study showed that, compared with a modest fish intake, a higher fish intake was associated with a substantially reduced risk of coronary heart disease, primarily nonfatal cardiac events, among middle-aged individuals22). In the Netherlands, mortality rates from CVD were >50% lower in patients who consumed at least 30 g/day of fish than in those who did not consume fish, suggesting that the consumption of one or two fish dishes per week prevents CVD23). A meta-analysis performed by Wang et al. showed that an increased consumption of n-3 PUFAs from fish or fish oil supplements, but not of ALA, reduces all-cause mortality, cardiac death, and sudden death rates24). He et al. showed an inverse association between n-3 PUFA intake and the prevalence of CVD25). These epidemiologic population studies showed that a reduced n-3 PUFA intake is a risk factor for cardiovascular events.

Randomized Controlled Trials Show that n-3 PUFAs Prevent Cardiovascular Events

For the primary prevention of CVD, the Japan EPA Lipid Intervention Study (JELIS), a randomized trial of 18,645 patients with hypercholesterolemia showed a 19% reduction in major cardiovascular events in patients randomized to a statin+highly purified EPA 1800 mg/day compared with those randomized to a statin alone5). For the secondary prevention of CVD, the DART study, a randomized controlled trial performed in the United Kingdom, showed that patients who recovered from myocardial infarction and advised to eat fatty fish had a 29% reduction in the 2-year all-cause mortality compared with those who were advised to reduce their fat intake and increase their cereal fiber intake26). GISSI-Prevenzi-

n-3 PUFAs for CVD

1001
not observed in patients with a low level of EPA after acute myocardial infarction\(^2\), and that higher plasma DHA, but not EPA, is associated with the reduced progression of coronary atherosclerosis in women with coronary artery disease (CAD)\(^29\). These results suggest that DHA exerts a protective effect on CAD and indicates the possibility that the administration of DHA can reduce cardiovascular events.

We showed that the combination of EPA and DHA has additional anti-inflammatory and anti-atherosclerotic effects with Western-type diet-fed Apoe\(^{-/-}\) mice (Fig. 2)\(^{30}\). In this study, high-dose EPA + DHA more effectively reduced atherogenesis than did EPA alone, in which the amount of EPA in these two treatments was similar. In addition, low-dose EPA + DHA, in which half the amount of EPA in the EPA group was replaced with a similar amount of DHA, demonstrated similar suppression of atherogenesis as that in the EPA group\(^{30}\).

### Differential Effects of DHA and EPA

Clinical studies have shown the effects of fish oil and n-3 PUFAs on cardiovascular events; however, the differential effects of DHA and EPA have been less well established. It has been reported that a low level of DHA is associated with all-cause death, which was
EPA\textsuperscript{31}. The bioavailability of DHA may explain the preferable effects of DHA on anti-atherosclerogenesis. Large clinical trials have shown the evidence of the effects of EPA or fish oil on the decrease in cardiovascular events; however, there has been no large clinical trial to show the preferable effects of DHA on cardiovascular events. Thus, large, clinical cohort studies are needed to clarify the differential effects of EPA and DHA on preventing cardiovascular events.

**Mechanisms by which n-3 PUFAs Prevent CVD: Attenuating All Atherogenic Features**

1) **Endothelial Dysfunction**

Endothelial dysfunction caused by a loss of endothelium-derived nitric oxide initiates atherosclerotic formation\textsuperscript{32}. The accumulation of lifestyle-related diseases triggers endothelial damage at the sites of disturbed laminar flow, such as branches, bifurcations, and curvatures, which lead to the breakdown of endothelial continuity\textsuperscript{39}.

A meta-analysis of 16 randomized placebo-controlled trials including 901 participants showed that n-3 PUFA intake increased the flow-mediated vasodilatation, which is a noninvasive measure of nitric oxide dependent on endothelial function, by 2.30\% (\(P=0.001\)) at a dose of 0.45–4.5 g/day over a median 56 days compared with placebo\textsuperscript{33}. Our observational study showed that serum DHA levels, but not EPA levels, in patients with CAD is associated with endothelial function when evaluated by flow-mediated vasodilatation, suggesting that a low serum DHA level is a risk factor for endothelial dysfunction, leading to CVD\textsuperscript{34}. A double-blind placebo-controlled trial showed that DHA, but not EPA, enhances vasodilation in response to acetylcholine, which induces endogenous nitric oxide release\textsuperscript{35, 36}.

It was reported that n-3 PUFAs enhance endothelial nitric oxide synthase (eNOS) expression and activation, leading to vasodilation\textsuperscript{37, 38}. n-3 PUFAs induce the translocation of eNOS from caveolin in the cell membrane to the cytosol, leading to eNOS system enhancement and activation, which may be a reason for n-3 PUFA-induced vasodilation\textsuperscript{39}. Another study showed that vascular endothelial dysfunction induced by palmitic acid, which is a saturated fatty acid, is attenuated by EPA treatment by the inhibition of long-chain acyl-CoA synthase expression\textsuperscript{40}. Thus, endothelial dysfunction may be ameliorated by n-3 PUFAs via eNOS-dependent or eNOS-independent mechanisms.

2) **Lipid Accumulation**

Endothelial damage evokes the subendothelial retention of cholesterol-containing plasma lipoproteins in coronary arteries. LDL and triglyceride-rich lipoproteins (remnant cholesterol) enter the subendothelial space via the damaged endothelial layer. LDL receives oxidative modifications to oxidized LDL, and small-dense LDL is more easily oxidized. Subsequently, oxidized LDL and triglyceride-rich lipoproteins could be taken up by macrophages for clearance, leading to vascular inflammation\textsuperscript{41}.

n-3 PUFAs reduce plasma triglycerides by approximately 20\%–30\% but have minimal effects on total, high-density lipoprotein, and LDL cholesterol\textsuperscript{42}. A meta-analysis of 17 large population-based studies showed that a high triglyceride level is an independent risk factor for CVD\textsuperscript{43}. However, compared with decreases in LDL cholesterol, insufficient data are available to document CVD benefits from decreases in plasma triglyceride in randomized placebo-controlled trials\textsuperscript{44}.

EPA reportedly reduces serum small-dense LDL and remnant lipoprotein particles in metabolic syndrome\textsuperscript{45}. The reduction of small-dense LDL by EPA treatment is due to the suppression of triglyceride production in the liver by EPA\textsuperscript{46}. Thus, n-3 PUFA treatment reduces the substrate of oxidative LDL or remnant cholesterol taken up by macrophages.

3) **Vascular Inflammation and Macrophage Recruitment**

Endothelial damage that occurs after lipid accumulation increases the adhesion of leukocytes to the endothelium by upregulating the expression of adhesion molecules, such as intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), E-selectin, or P-selectin, and enhances their leukocyte permeability to sub-endothelium. Thus, adhesion molecules are critical to the initiation of vascular inflammation. The injured endothelium releases cytokines and growth factors, such as monocyte chemoattractant protein 1 (MCP-1) that act as chemotactic factors attracting monocytes and T cells to the vessel wall, resulting in vascular inflammation\textsuperscript{46}. Inflammatory conditions recruit circulating monocytes and develop them into macrophages in the sub-endothelium.

Several randomized clinical trials have shown that n-3 PUFAs decrease the expression of cell adhesion molecules (e.g. VCAM-1, ICAM-1, and E-selectin)\textsuperscript{47}. In vitro studies have shown that DHA, but not EPA, decreased the expression of cell adhesion molecules and monocyte adhesion to endothelial cells\textsuperscript{48}. n-3 PUFAs attenuated the expression of adhesion molecules on the surface of cultured human endothelial cells, monocytes, and lymphocytes\textsuperscript{48}. The n-3 PUFA-induced attenuation of the expression of adhesion molecules was accompanied by a decreased binding of human lymphocytes and monocytes to cytokine-stimulated...
endothelial cells. It has been shown that resolvins and G protein-coupled receptor 120, which are metabolites of EPA and DHA, play crucial roles in the active resolution of inflammation and are involved in the mechanisms of n-3 PUFA-induced anti-inflammatory effects. An ex vivo and animal study showed that n-3 PUFAs reduce the production of pro-inflammatory cytokines, including tumor necrosis factor (TNF)-α, interleukin (IL)-1, and IL-6, following the lipopolysaccharide (LPS) stimulation of monocytes/lymphocytes. Clinical studies have shown that fish oil supplementation may inhibit the production of cytokines, including IL-1β and TNF-α.

The molecular mechanism of the anti-inflammatory effects of n-3 PUFAs has not been fully elucidated. The plasma membrane comprises a lipid raft, phospholipid bilayer with cholesterol microdomains, sphingolipids, and lipid-anchored proteins, and plays a crucial role in signal transduction as a signaling platform. Cell membranes with n-3 PUFA-rich phospholipids have an increased fluidity than those with n-6 PUFA-rich phospholipids.

Toll-like receptor (TLR) 4 is the receptor for LPS, which plays a critical role in the inflammatory signaling pathway, including the nuclear factor-kappa β pathway. TLR4 stimulation induces the expression of pro-inflammatory cytokines and chemokines in various cell types, leading to the activation of NLR family pyrin domain containing (NLRP) 3 inflammasome when combined with the uptake or intracellular formation of cholesterol crystals. The most crucial TLR ligands are thought to be modified forms of LDL in atherosclerosis in addition to LPS. The initial step in signal transduction by TLR4 is the dimerization of two receptor chains induced by the binding of myeloid differentiation factor (MD)-2 to the lipid A moiety of LPS. Enhancing the dimerization of the cell membrane fluidity of the two receptor chains is important. We showed that n-3 PUFA treatment to the Western-type diet-fed Apoe−/− mice significantly decreased the progression of atherosclerotic lesions and TLR4 expression in lipid rafts on macrophages. These results suggested that n-3 PUFAs modify TLR4 localization by attenuating TLR4 dimerization on the cell membrane, resulting in inhibited TLR4 expression (Fig. 3).

4) Plaque Development through the Proliferation and Migration of SMCs

The resulting increase in chemotactic factors stimulates the proliferation and migration of SMCs and further accumulation of inflammatory cells, leading to neointima formation. These inflammatory cells and SMCs are thought to migrate from the bloodstream and proliferate within the lesion. Atherosclerosis is thought to progress “inside-out” from the endothelium to the adventitia. A recent study has elucidated that atherosclerotic plaque growth is accompanied by a network of microvessels, called the vasa vasorum, extend-
ing from the adventitia into the base of the plaque. The vasa vasorum supplies oxygen and nutrients to the outer layers of the arterial wall. It is believed that inflammatory cytokines and chemotactic factors stimulate SMC migration via the vasa vasorum. Thus, the concept that the atherosclerotic process extends not only inside-out but also "outside-in" is widely believed. SMC migration contributes to plaque buildup.

It has been shown that n-3 PUFAs block SMC proliferation and migration. We demonstrated that EPA treatment reduced SMC proliferation and atherosclerotic lesion development in Apoe−/− mice fed a Western-type diet. An abundant development of the vasa vasorum around the coronary artery of a hypercholesterolemic pig showed an enhanced expression of the vascular endothelial growth factor (VEGF). Statins reportedly attenuate the neovascularization of the vasa vasorum via VEGF inhibition. EPA attenuates the tube formation of endothelial cells via its inhibitory effect on cellular proliferation. Thus, n-3 PUFAs could inhibit the neovascularization of the vasa vasorum and reduce the migration of SMCs and inflammatory cells, leading to the suppression of plaque development.

5) Plaque Vulnerability Leading to Plaque Rupture

Ultimately, inflammatory mediators can inhibit collagen synthesis and evoke collagenase expression by foam cells within the intimal lesion. Macrophages internalize cholesterol through their scavenger receptors and produce inflammatory cytokines and collagenases, including matrix metalloproteinases (MMPs). MMPs cause thinning of the fibrous cap and render it weak and susceptible to rupture at the plaque shoulder, leading to plaque rupture. The subendothelial tissue factor is then uncovered, and the tissue factor induced by the inflammatory signaling triggers thrombus formation, resulting in ACS.

Nozue et al. have shown that decrease in serum n-3 to n-6 polyunsaturated fatty acid ratio is associated with the progression of coronary atherosclerosis, which was evaluated using virtual histology intravascular ultrasound in statin-treated patients with CAD. We showed that EPA treatment in addition to statin treatment reduced lipid volume in coronary plaques, which was evaluated by integrated backscatter intravascular ultrasound, and decreased inflammatory cytokines including pentraxin 3 and MCP-1.

A histological study showed that carotid atherosclerotic plaques from patients treated with fish oil were less heavily infiltrated with macrophages than in those in the placebo group. Moreover, plaques from patients treated with fish oil were more likely to be fibrous-cap atheromas and display fewer signs of inflammation than those treated with placebo, indicating that fish oil increases plaque stability.

Decreased EPA/AA ratios were identified in young Japanese subjects. Decreased EPA/AA and DHA/AA ratios are known risk factors for early-onset ACS, suggesting that reduced EPA/AA and DHA/AA ratios may represent targets for preventing ACS in young Japanese people. There is a high prevalence of coronary atherosclerosis in asymptomatic young people, suggesting that n-3 PUFA intake from a young age might be needed to prevent future ACS.

Taken together, n-3 PUFAs attenuate all the above features of atherogenesis similar to statins (Fig. 4).

Other Preferable Effects of n-3 PUFAs for Preventing CVD

1) n-3 PUFAs Prevent Cardiac Remodeling and Heart Failure

CVD events eventually lead to heart failure. The OMEGA-REMODEL randomized clinical trial has shown that high-dose n-3 PUFA treatment in patients with acute myocardial infarction was associated with reduced adverse left ventricular remodeling, non-infarct myocardial fibrosis, evaluated by cardiac magnetic resonance and serum biomarkers of systemic inflammation beyond the current guideline-based standard of care. GISSI HF investigated whether n-3 PUFA could improve morbidity and mortality rates in a large population of patients with symptomatic heart failure of any cause. The findings of this study indicated that n-3 PUFAs have preferable effects on cardiac remodeling and heart failure.

2) n-3 PUFAs Attenuates Ventricular Arrhythmia

The onset of CVD and/or heart failure induces fatal ventricular arrhythmia. Epidemiological studies have shown that n-3 PUFA intake reduced sudden cardiac death and ventricular arrhythmias and showed an inverse relationship between n-3 PUFA concentration and the prevalence of sudden cardiac death. n-3 PUFAs may have profound effects on the trafficking of ion channels through subcellular compartments and within lipid rafts. In addition, n-3 PUFAs can inhibit the Na+ current and several different K+ currents in a dose-dependent manner and can modulate or attenuate Ca2+ influx into cardiomyocytes and sodium–calcium exchanger system. These mechanisms may contribute to the anti-arrhythmic effects of n-3 PUFAs that lead to the prevention of sudden cardiac death.

We reported that low serum EPA and DHA levels are risk factors for cardiogenic syncope in patients with Brugada syndrome. Although the etiology of
Although the mechanisms by which n-3 PUFAs improve exercise capacity has not been fully elucidated, it is known that the incorporation of n-3 PUFAs into myocardial and skeletal muscle membranes leads to the modification of skeletal muscle function and increases insulin sensitivity and that of n-3 PUFAs into erythrocytes leads to the modification of erythrocyte rheology, which might be involved in n-3 PUFA-induced increases in exercise capacity.

Who Should Take n-3 PUFAs?
Patients with CVD and Heart Failure

The effects of n-3 PUFAs on CVD prevention seems modest compared with those of statins, and the best candidates to receive the benefits of n-3 PUFAs on CVD prevention are yet to be identified. A recent recommendation from the American Heart Association suggests that n-3 PUFA supplementation in patients with CVD for secondary prevention and those with heart failure is reasonable from randomized control trials. However, further large-scale clinical trials are needed to identify the best candidates for n-3 PUFA supplementation to prevent CVD because of a lack of evidence.

Conclusions

A growing body of evidence suggests that n-3 PUFAs have beneficial effects for preventing CVD in
this era of statins, n-3 PUFAs suppress atherosclerosis via pleiotropic effects in addition to modifying lipid profiles. Thus, n-3 PUFA intake is recommended to prevent CVD, particularly in patients with multiple cardiovascular risk factors.

Conflict of Interest

M. Sata received research funding from Tanabe-Mitsubishi, Takeda, Astellas, Byer Healthcare, Daichish-Sankyo, MSD, and Ono and lecture fees from Astellas, Boehringer Ingelheim, Byer Healthcare, Mochida, Takeda, Tanabe-Mitsubishi, Novartis, AstraZeneca, MSD, and Shionogi. The Department of Cardio-Diabetes Medicine, Tokushima University Graduate School is supported in part by unrestricted research grants from Actelion, Boehringer Ingelheim, Kowa, and Tanabe-Mitsubishi. The others declare that they have no conflicts of interest to disclose.

References

4) Das UN: Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules. Lipids Health Dis 2008, 7: 37
23) Kromhout D, Bosschieter EB, de Lezenne Coulander C: The inverse relation between fish consumption and 20-year

1007
52) Tall AR, Yvan-Charvet L: Cholesterol, inflammation and innate immunity. Nat Rev Immunol 2015, 15: 104-116
77) Yagi S, Akaike M, Isé T, Ueda Y, Iwase T, Sata M: Renin-angiotensin-aldosterone system has a pivotal role in cognitive impairment. Hypertens Res 2013, 36: 753-758
84) Da Boit M, Hunter AM, Gray SR: Fit with good fat? The role of n-3 polyunsaturated fatty acids on exercise performance. Metabolism 2017, 66: 45-54